Search results
Showing 1906 to 1920 of 2004 results for nice guidelines
This guidance has been updated and replaced by NICE guideline CG181.
Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)
This guidance has been updated and replaced by NICE guideline CG186.
This guidance has been updated and replaced by NICE guideline NG130.
This guidance has been updated and replaced by NICE guideline NG92.
This evidence summary has been updated and replaced by NICE guideline NG97.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.